© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to August
oral plasma kallikrein serine protease inhibitor
approved for prevention of HAE attacks
from structure-based drug design
Journal of Medicinal Chemistry
BioCryst, Birmingham, AL, USA
The Biocryst oral plasma kallikrein inhibitor, berotralstat (BCX7353), was recently approved as the first non-steroidal treatment for prevention of hereditary angioedema attacks. The molecule is given orally (150 mg QD) despite having…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.